Close Menu

inflammatory bowel disease

Researchers from BGI Shenzhen and elsewhere used a metagenomics approach to identify and characterize the microbial genes found in the human gut.

The exclusive sales and marketing agreement covers gene expression tests for inflammatory bowel disease and irritable bowel syndrome.

The company also remains on track with its more advanced familial adenomatous polyposis drug and plans to file within the next two weeks an investigational new drug application to begin testing the therapy in humans.

OSU Medical Center will enroll patients who agree to join Coriell's personalized medicine project under the guidance of their primary care physician. The partners will study the impact of using genomic information in treating chronic conditions.

The technology, called glucan-encapsulated siRNA particles, or GERPs, has been exclusively licensed by RXi Pharmaceuticals for use in developing RNAi-based therapeutics.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

An NIH panel sees wide-ranging needs for genomics, biomarker studies, and new facilities in order to tackle major digestive disorders.

MDRNA also reported its fourth-quarter financial results, posting lower operating costs on the elimination of non-RNAi programs and operations the company was working on prior to a corporate reorganization.

Under terms of the deal, Novartis will give Epistem a $4 million upfront payment and provide funding to study the stem cell shop's drug targets. Epistem could also get up to $45 million in milestone payments for each product developed from targets licensed under the agreement.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.